Literature DB >> 17682104

Contributions of the combined effects of topoisomerase mutations toward fluoroquinolone resistance in Escherichia coli.

Sonia K Morgan-Linnell1, Lynn Zechiedrich.   

Abstract

In defined, isogenic strains, at least three mutations, two of which must be in gyrA, were required to exceed the CLSI breakpoint for fluoroquinolone resistance. Strains with double mutations in both gyrA and parC had even higher MICs of fluoroquinolones than strains with totals of three mutations.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17682104      PMCID： PMC2151436          DOI： 10.1128/AAC.00647-07

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  20 in total

1.  In vitro activity of gemifloxacin and five other fluoroquinolones against defined isogenic mutants of Escherichia coli, Pseudomonas aeruginosa and Staphylococcus aureus.

Authors:  A Schulte; P Heisig
Journal:  J Antimicrob Chemother       Date:  2000-12       Impact factor: 5.790

2.  Impact of gyrA and parC mutations on quinolone resistance, doubling time, and supercoiling degree of Escherichia coli.

Authors:  S Bagel; V Hüllen; B Wiedemann; P Heisig
Journal:  Antimicrob Agents Chemother       Date:  1999-04       Impact factor: 5.191

3.  Segregation of New Lysogenic Types during Growth of a Doubly Lysogenic Strain Derived from Escherichia Coli K12.

Authors:  R K Appleyard
Journal:  Genetics       Date:  1954-07       Impact factor: 4.562

4.  Roles of topoisomerase IV and DNA gyrase in DNA unlinking during replication in Escherichia coli.

Authors:  E L Zechiedrich; N R Cozzarelli
Journal:  Genes Dev       Date:  1995-11-15       Impact factor: 11.361

Review 5.  Mechanisms of action of antimicrobials: focus on fluoroquinolones.

Authors:  D C Hooper
Journal:  Clin Infect Dis       Date:  2001-03-15       Impact factor: 9.079

Review 6.  Mechanism of fluoroquinolone action.

Authors:  K Drlica
Journal:  Curr Opin Microbiol       Date:  1999-10       Impact factor: 7.934

7.  Gatifloxacin activity against quinolone-resistant gyrase: allele-specific enhancement of bacteriostatic and bactericidal activities by the C-8-methoxy group.

Authors:  T Lu; X Zhao; K Drlica
Journal:  Antimicrob Agents Chemother       Date:  1999-12       Impact factor: 5.191

Review 8.  Mechanisms of action and resistance of older and newer fluoroquinolones.

Authors:  D C Hooper
Journal:  Clin Infect Dis       Date:  2000-08       Impact factor: 9.079

9.  DNA topoisomerase targets of the fluoroquinolones: a strategy for avoiding bacterial resistance.

Authors:  X Zhao; C Xu; J Domagala; K Drlica
Journal:  Proc Natl Acad Sci U S A       Date:  1997-12-09       Impact factor: 11.205

10.  Fluoroquinolone prescribing in the United States: 1995 to 2002.

Authors:  Jeffrey A Linder; Elbert S Huang; Michael A Steinman; Ralph Gonzales; Randall S Stafford
Journal:  Am J Med       Date:  2005-03       Impact factor: 4.965
View more
  30 in total

1.  Temporal interplay between efflux pumps and target mutations in development of antibiotic resistance in Escherichia coli.

Authors:  Renu Singh; Michelle C Swick; Kimberly R Ledesma; Zhen Yang; Ming Hu; Lynn Zechiedrich; Vincent H Tam
Journal:  Antimicrob Agents Chemother       Date:  2012-01-09       Impact factor: 5.191

2.  In vitro effect of qnrA1, qnrB1, and qnrS1 genes on fluoroquinolone activity against isogenic Escherichia coli isolates with mutations in gyrA and parC.

Authors:  A Briales; J M Rodríguez-Martínez; C Velasco; P Díaz de Alba; J Domínguez-Herrera; J Pachón; A Pascual
Journal:  Antimicrob Agents Chemother       Date:  2010-12-20       Impact factor: 5.191

3.  Use of an in vitro pharmacodynamic model to derive a moxifloxacin regimen that optimizes kill of Yersinia pestis and prevents emergence of resistance.

Authors:  A Louie; H S Heine; B VanScoy; A Eichas; K Files; S Fikes; D L Brown; W Liu; M Kinzig-Schippers; F Sörgel; G L Drusano
Journal:  Antimicrob Agents Chemother       Date:  2010-11-29       Impact factor: 5.191

4.  Relationships among ciprofloxacin, gatifloxacin, levofloxacin, and norfloxacin MICs for fluoroquinolone-resistant Escherichia coli clinical isolates.

Authors:  Lauren Becnel Boyd; Merry J Maynard; Sonia K Morgan-Linnell; Lori Banks Horton; Richard Sucgang; Richard J Hamill; Javier Rojo Jimenez; James Versalovic; David Steffen; Lynn Zechiedrich
Journal:  Antimicrob Agents Chemother       Date:  2008-10-06       Impact factor: 5.191

5.  Mechanisms accounting for fluoroquinolone resistance in Escherichia coli clinical isolates.

Authors:  Sonia K Morgan-Linnell; Lauren Becnel Boyd; David Steffen; Lynn Zechiedrich
Journal:  Antimicrob Agents Chemother       Date:  2008-10-06       Impact factor: 5.191

6.  Molecular characterization of extraintestinal Escherichia coli isolates in Japan: relationship between sequence types and mutation patterns of quinolone resistance-determining regions analyzed by pyrosequencing.

Authors:  Nozomi Aoike; Tomoo Saga; Ryuji Sakata; Ayumi Yoshizumi; Soichiro Kimura; Morihiro Iwata; Sadako Yoshizawa; Yasuyuki Sugasawa; Yoshikazu Ishii; Keizo Yamaguchi; Kazuhiro Tateda
Journal:  J Clin Microbiol       Date:  2013-03-20       Impact factor: 5.948

7.  Novel Conserved Genotypes Correspond to Antibiotic Resistance Phenotypes of E. coli Clinical Isolates.

Authors:  Michelle C Swick; Michael A Evangelista; Truston J Bodine; Jeremy R Easton-Marks; Patrick Barth; Minita J Shah; Christina A Bormann Chung; Sarah Stanley; Stephen F McLaughlin; Clarence C Lee; Vrunda Sheth; Quynh Doan; Richard J Hamill; David Steffen; Lauren B Becnel; Richard Sucgang; Lynn Zechiedrich
Journal:  PLoS One       Date:  2013-06-18       Impact factor: 3.240

8.  Specific patterns of gyrA mutations determine the resistance difference to ciprofloxacin and levofloxacin in Klebsiella pneumoniae and Escherichia coli.

Authors:  Yingmei Fu; Wenli Zhang; Hong Wang; Song Zhao; Yang Chen; Fanfei Meng; Ying Zhang; Hui Xu; Xiaobei Chen; Fengmin Zhang
Journal:  BMC Infect Dis       Date:  2013-01-07       Impact factor: 3.090

9.  Quinolone resistance in Escherichia coli from Accra, Ghana.

Authors:  Sreela S Namboodiri; Japheth A Opintan; Rebeccah S Lijek; Mercy J Newman; Iruka N Okeke
Journal:  BMC Microbiol       Date:  2011-02-27       Impact factor: 3.605

10.  A fluoroquinolone resistance associated mutation in gyrA Affects DNA supercoiling in Campylobacter jejuni.

Authors:  Jing Han; Yang Wang; Orhan Sahin; Zhangqi Shen; Baoqing Guo; Jianzhong Shen; Qijing Zhang
Journal:  Front Cell Infect Microbiol       Date:  2012-03-01       Impact factor: 5.293
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.